Chemistry:CRL-40,940

From HandWiki
Revision as of 00:10, 6 February 2024 by Wincert (talk | contribs) (correction)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Wakefulness promoting drug/Dopamine reuptake inhibitor
CRL-40,940
CRL-40,940.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H13F2NO2S
Molar mass309.33 g·mol−1
3D model (JSmol)

CRL-40,940 (also known as flmodafinil, bisfluoromodafinil and lauflumide) is the bisfluoro analog of modafinil.[1][2][3][4][5] It is a eugeroic as well as a weak dopamine reuptake inhibitor. Its inventors claim that it is more effective than modafinil and adrafinil, with fewer side effects. It was patented in 2013, and pre-clinical trials have been underway since December 2015.[6]

See also

References

  1. Lafon L, "Benzhydrylsulfinylacetamide derivatives", CA patent 1199916, published 28 January 1986
  2. "Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinylacetamide) Analogues"]. ACS Medicinal Chemistry Letters 2 (1): 48–52. October 2010. doi:10.1021/ml1002025. PMID 21344069. 
  3. Konofal E, "Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof", US patent 20130295196, published 7 November 2013
  4. "Flmodafinil Dosage: How Much Should You Take and When?". https://modaforum.org/viewtopic.php?p=395&hilit=CRL+40,940#p395. 
  5. Louis Lafon (18 December 1984). "Patent US 4489095 A - Halogenobenzhydrylsulfinylacetohydroxamic acids". https://www.google.com/patents/US4489095. 
  6. "Pipeline". NLS Pharmaceuticals. http://nlspharma.com/science/pipeline/.